Ben Harrington’s M&A focused Betaville blog remarked on rumors surrounding Paratek Pharmaceuticals, contacts tell The Fly.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PRTK:
- Paratek price target lowered to $10 from $20 at H.C. Wainwright
- Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million
- Paratek Pharmaceuticals sees FY23 revenue $143M-$158M, consensus $232.02M
- Paratek Pharmaceuticals reports Q4 EPS (13c), consensus 9c
- Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16